Literature DB >> 23912961

Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Michelle C Specht1, Cynthia L Miller, Tara A Russell, Nora Horick, Melissa N Skolny, Jean A O'Toole, Lauren S Jammallo, Andrzej Niemierko, Betro T Sadek, Mina N Shenouda, Dianne M Finkelstein, Barbara L Smith, Alphonse G Taghian.   

Abstract

The purpose of this study is to evaluate arm volume measurements and clinico-pathologic characteristics of breast cancer patients to define a threshold for intervention in breast cancer-related lymphedema. We prospectively performed arm volume measurements on breast cancer patients using a Perometer. Arm measurements were performed pre- and post-operatively, and change in arm volume was quantified using a relative volume change (RVC) equation. Patient and treatment risk factors were evaluated. Cox proportional hazards models with time-dependent covariates for RVC were used to evaluate whether RVC elevations of ≥3 to <5 % or ≥5 to <10 % occurring ≤3 months or >3 months after surgery were associated with progression to ≥10 % RVC. 1,173 patients met eligibility criteria with a median of 27 months post-operative follow-up. The cumulative incidence of ≥10 % RVC at 24 months was 5.26 % (95 % CI 4.01-6.88 %). By multivariable analysis, a measurement of ≥5 to <10 % RVC occurring >3 months after surgery was significantly associated with an increased risk of progression to ≥10 % RVC (HR 2.97, p < 0.0001), but a measurement of ≥3 to <5 % RVC during the same time period was not statistically significantly associated (HR 1.55, p = 0.10). Other significant risk factors included a measurement ≤3 months after surgery with RVC of ≥3 to <5 % (p = 0.007), ≥5 to <10 % (p < 0.0001), or ≥10 % (p = 0.023), axillary lymph node dissection (ALND) (p < 0.0001), and higher BMI at diagnosis (p = 0.0028). Type of breast surgery, age, number of positive or number of lymph nodes removed, nodal radiation, chemotherapy, and hormonal therapy were not significant (p > 0.05). Breast cancer patients who experience a relative arm volume increase of ≥3 to <5 % occurring >3 months after surgery do not have a statistically significant increase in risk of progression to ≥10 %, a common lymphedema criterion. Our data support utilization of a ≥5 to <10 % threshold for close monitoring or intervention, warranting further assessment. Additional risk factors for progression to ≥10 % include ALND, higher BMI, and post-operative arm volume elevation.

Entities:  

Mesh:

Year:  2013        PMID: 23912961      PMCID: PMC3788652          DOI: 10.1007/s10549-013-2655-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  65 in total

1.  A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population.

Authors:  Jane M Armer; Bob R Stewart
Journal:  Lymphat Res Biol       Date:  2005       Impact factor: 2.589

2.  The impact of breast cancer among Canadian women: disability and productivity.

Authors:  Elizabeth Quinlan; Roanne Thomas-MacLean; Tom Hack; Winkle Kwan; Baukje Miedema; Sue Tatemichi; Anna Towers; Andrea Tilley
Journal:  Work       Date:  2009

Review 3.  Incidence of breast carcinoma-related lymphedema.

Authors:  J A Petrek; M C Heelan
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

Review 4.  Arm edema in breast cancer patients.

Authors:  V S Erickson; M L Pearson; P A Ganz; J Adams; K L Kahn
Journal:  J Natl Cancer Inst       Date:  2001-01-17       Impact factor: 13.506

5.  Minimal limb volume change has a significant impact on breast cancer survivors.

Authors:  J N Cormier; Y Xing; I Zaniletti; R L Askew; B R Stewart; J M Armer
Journal:  Lymphology       Date:  2009-12       Impact factor: 1.286

6.  Prognostic factors for lymphedema after primary treatment of breast carcinoma.

Authors:  A Herd-Smith; A Russo; M G Muraca; M R Del Turco; G Cardona
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

7.  An audit of the incidence of arm lymphoedema after prophylactic level I/II axillary dissection without division of the pectoralis minor muscle.

Authors:  G Querci della Rovere; I Ahmad; P Singh; S Ashley; I R Daniels; P Mortimer
Journal:  Ann R Coll Surg Engl       Date:  2003-05       Impact factor: 1.891

8.  Preoperative assessment enables the early diagnosis and successful treatment of lymphedema.

Authors:  Nicole L Stout Gergich; Lucinda A Pfalzer; Charles McGarvey; Barbara Springer; Lynn H Gerber; Peter Soballe
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

9.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

10.  Lymphedema after treatment of breast cancer.

Authors:  Cihangir Ozaslan; Bekir Kuru
Journal:  Am J Surg       Date:  2004-01       Impact factor: 2.565

View more
  29 in total

1.  Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures.

Authors:  J M Blaney; G McCollum; J Lorimer; J Bradley; R Kennedy; J P Rankin
Journal:  Support Care Cancer       Date:  2014-11-16       Impact factor: 3.603

2.  In reply.

Authors:  Jean O'Toole; Lauren S Jammallo; Cynthia L Miller; Melissa N Skolny; Michelle C Specht; Alphonse G Taghian
Journal:  Oncologist       Date:  2013

3.  Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk?

Authors:  Susan G R McDuff; Amir I Mina; Cheryl L Brunelle; Laura Salama; Laura E G Warren; Mohamed Abouegylah; Meyha Swaroop; Melissa N Skolny; Maria Asdourian; Tessa Gillespie; Kayla Daniell; Hoda E Sayegh; George E Naoum; Hui Zheng; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-28       Impact factor: 7.038

4.  The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients.

Authors:  Rachel K Voss; Kate D Cromwell; Yi-Ju Chiang; Jane M Armer; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Bob R Stewart; Simona F Shaitelman; Janice N Cormier
Journal:  J Surg Oncol       Date:  2015-10-18       Impact factor: 3.454

5.  Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.

Authors:  Fangdi Sun; Alexander Hall; Megan P Tighe; Cheryl L Brunelle; Hoda E Sayegh; Tessa C Gillespie; Kayla M Daniell; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2018-07-30       Impact factor: 4.872

Review 6.  The impact of radiation on lymphedema: a review of the literature.

Authors:  Omar Allam; Kitae E Park; Ludmila Chandler; Mohammad Ali Mozaffari; Maham Ahmad; Xiaona Lu; Michael Alperovich
Journal:  Gland Surg       Date:  2020-04

7.  Hand Edema in Patients at Risk of Breast Cancer-Related Lymphedema: Health Professionals Should Take Notice.

Authors:  Cheryl L Brunelle; Meyha N Swaroop; Melissa N Skolny; Maria S Asdourian; Hoda E Sayegh; Alphonse G Taghian
Journal:  Phys Ther       Date:  2018-06-01

8.  Lymphoedema and health-related quality of life by early treatment in long-term survivors of breast cancer. A comparative retrospective study up to 15 years after diagnosis.

Authors:  Katarina Y Karlsson; Imke Wallenius; Lena B Nilsson-Wikmar; Henrik Lindman; Birgitta B K Johansson
Journal:  Support Care Cancer       Date:  2015-03-06       Impact factor: 3.603

Review 9.  Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.

Authors:  Sarah A McLaughlin; Cheryl L Brunelle; Alphonse Taghian
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

10.  Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer.

Authors:  Ann Marie Flores; Jason Nelson; Lee Sowles; Rebecca G Stephenson; Kathryn Robinson; Andrea Cheville; Antoinette P Sander; William J Blot
Journal:  Phys Ther       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.